Literature DB >> 33446046

Accelerated cardiovascular risk after viral clearance in hepatitis C patients with the NAMPT-rs61330082 TT genotype: An 8-year prospective cohort study.

Ming-Ling Chang1,2, Yu-Sheng Lin3,4, Ming-Yu Chang5,6, Chia-Lin Hsu7, Rong-Nan Chien1,2, Cathy Sj Fann7.   

Abstract

Involvement of extracellular nicotinamide phosphoribosyltransferase (eNAMPT, i.e., visfatin or pre-B-cell colony-enhancing factor), a cancer metabokine, in chronically hepatitis C virus (HCV)-infected (CHC) patients with sustained virological responses (SVRs) remains elusive. This 8-year prospective cohort study evaluated eNAMPT profiles of 842 consecutive CHC patients, including 519 who had completed an anti-HCV therapy course and pre-therapy and 24-week post-therapy surveys. For 842 patients, pre-therapy associations were HCV RNA, homeostatic model assessment for insulin resistance (HOMA-IR) index, and body mass index with eNAMPT levels, and NAMPT-rs61330082 T allele with total cholesterol levels. NAMPT-rs10953502, NAMPT-rs2058539, and NAMPT-rs61330082 were in a linkage disequilibrium block, which was associated with total cholesterol levels. Compared to pre-therapy levels, at 24 weeks post-therapy, decreased eNAMPT and increased lipid levels were observed in SVR patients (n = 427). Among SVR patients, higher cumulative incidences of cardiovascular events occurred in those with a NAMPT-rs61330082 TT genotype than those with non-TT genotypes (28.2% vs. 8.4%, p < 0.001). NAMPT-rs61330082 TT genotype was independently associated with incident cardiovascular events (95% CI hazard ratio (HR): 1.88-10.37; HR: 4.415); no eNAMPT profiles were associated with incident malignancies. Of CHC patients, hepatic vascular endothelial cells and baseline peripheral leukocytes expressed higher eNAMPT levels than controls, and peripheral eNAMPT-positive leukocyte proportions decreased after SVR. During HCV infection, eNAMPT involvement in glucose metabolism was modulated by HCV RNA linked to lipid metabolism and NAMPT-associated SNPs. Hepatic endothelial cells and peripheral leukocytes potentially secrete eNAMPT. Caution is required for incident cardiovascular events in SVR patients with NAMPT-rs61330082 TT genotype.

Entities:  

Keywords:  HCV; NAMPT-rs61330082; cardiovascular; pre-B-cell colony-enhancing factor; visfatin

Year:  2021        PMID: 33446046      PMCID: PMC7834047          DOI: 10.1080/21505594.2020.1870080

Source DB:  PubMed          Journal:  Virulence        ISSN: 2150-5594            Impact factor:   5.882


  47 in total

1.  The evolving relationship between adiponectin and insulin sensitivity in hepatitis C patients during viral clearance.

Authors:  Ming-Ling Chang; Chia-Jung Kuo; Li-Heng Pao; Chen-Ming Hsu; Cheng-Tang Chiu
Journal:  Virulence       Date:  2017-03-07       Impact factor: 5.882

2.  A comparison of major histocompatibility complex SNPs in Han Chinese residing in Taiwan and Caucasians.

Authors:  Hsin-Chou Yang; Chien-Hsin Lin; Chia-Ling Hsu; Shuen-Iu Hung; Jer-Yuan Wu; Wen-Harn Pan; Yuan-Tsong Chen; Cathy S J Fann
Journal:  J Biomed Sci       Date:  2006-03-17       Impact factor: 8.410

3.  Association of genetic variability in selected regions in visfatin (NAMPT) gene with anthropometric parameters and dietary composition in obese and non-obese Central-European population.

Authors:  Jiri Stastny; Julie Bienertova-Vasku; Josef Tomandl; Marie Tomandlova; Filip Zlamal; Martin Forejt; Zbynek Splichal; Anna Vasku
Journal:  Diabetes Metab Syndr       Date:  2013-07-18

4.  Identification of a Novel Hepatitis C Virus Genotype From Punjab, India: Expanding Classification of Hepatitis C Virus Into 8 Genotypes.

Authors:  Sergio M Borgia; Charlotte Hedskog; Bandita Parhy; Robert H Hyland; Luisa M Stamm; Diana M Brainard; Mani G Subramanian; John G McHutchison; Hongmei Mo; Evguenia Svarovskaia; Stephen D Shafran
Journal:  J Infect Dis       Date:  2018-10-20       Impact factor: 5.226

5.  Common polymorphisms in the promoter of the visfatin gene (PBEF1) influence plasma insulin levels in a French-Canadian population.

Authors:  Swneke D Bailey; J C Loredo-Osti; Pierre Lepage; Janet Faith; Joelle Fontaine; Katia M Desbiens; Thomas J Hudson; Claude Bouchard; Daniel Gaudet; Louis Pérusse; Marie-Claude Vohl; James C Engert
Journal:  Diabetes       Date:  2006-10       Impact factor: 9.461

6.  Genetic variants in NAMPT predict bladder cancer risk and prognosis in individuals from southwest Chinese Han group.

Authors:  Kui Zhang; Bin Zhou; Peng Zhang; Zhu Zhang; Peng Chen; Yan Pu; Yaping Song; Lin Zhang
Journal:  Tumour Biol       Date:  2013-12-22

7.  Correlation between polymorphisms in the visfatin gene and its expression in the serum and coronary artery calcification.

Authors:  L W Jin; S B Zheng; Z H Zhou; S F Pan; Y Zheng
Journal:  Genet Mol Res       Date:  2016-07-14

8.  A rare variant in the visfatin gene (NAMPT/PBEF1) is associated with protection from obesity.

Authors:  Alexandra I F Blakemore; David Meyre; Jerome Delplanque; Vincent Vatin; Cecile Lecoeur; Michel Marre; Jean Tichet; Beverley Balkau; Philippe Froguel; Andrew J Walley
Journal:  Obesity (Silver Spring)       Date:  2009-03-19       Impact factor: 5.002

Review 9.  Pre-B cell colony-enhancing factor (PBEF)/visfatin: a novel mediator of innate immunity.

Authors:  Tracy Luk; Zeenat Malam; John C Marshall
Journal:  J Leukoc Biol       Date:  2008-02-05       Impact factor: 4.962

10.  Link between plasminogen activator inhibitor-1 and cardiovascular risk in chronic hepatitis C after viral clearance.

Authors:  Ming-Ling Chang; Yu-Sheng Lin; Li-Heng Pao; Hsin-Chih Huang; Cheng-Tang Chiu
Journal:  Sci Rep       Date:  2017-02-13       Impact factor: 4.379

View more
  2 in total

1.  Association between Hepatitis C Virus Infection and Esophageal Cancer: An Asian Nationwide Population-Based Cohort Study.

Authors:  Yin-Yi Chu; Jur-Shan Cheng; Ting-Shu Wu; Chun-Wei Chen; Ming-Yu Chang; Hsin-Ping Ku; Rong-Nan Chien; Ming-Ling Chang
Journal:  J Clin Med       Date:  2021-05-28       Impact factor: 4.241

2.  Critical role of triglycerides for adiponectin levels in hepatitis C: a joint study of human and HCV core transgenic mice.

Authors:  Ming-Ling Chang; Jing-Hong Hu; Li-Heng Pao; Ming-Shyan Lin; Chia-Jung Kuo; Shiang-Chi Chen; Chun-Ming Fan; Ming-Yu Chang; Rong-Nan Chien
Journal:  BMC Immunol       Date:  2021-08-11       Impact factor: 3.615

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.